Study of Pemetrexed+Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Participants With First Line Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-3475-189/KEYNOTE-189)-Japan Extension Study
Condition: Non-Small-Cell Lung Carcinoma Interventions: Biological: Pembrolizumab 200 mg; Drug: Cisplatin; Drug: Carboplatin; Drug: Pemetrexed; Dietary Supplement: Folic acid 350-1000 μg; Dietary Supplement: Vitamin B12 1000 μg; Drug: Dexamethasone 4 mg; Drug: Saline solution Sponsor: Merck Sharp & Dohme Corp. Active, not recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Alimta | Cancer | Cancer & Oncology | Carcinoma | Chemotherapy | Japan Health | Lung Cancer | Non-Small Cell Lung Cancer | Nutrition | Research | Study